Evidence map›Paper›PMID 41081911›Full record

ArticleCancer immunology, immunotherapy : CII2025

CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor.

Yosuke Kogue, Shunya Ikeda, Yuto Maehara, Ryuhei Kawamoto, Makiko Suga, Shuhei Kida, Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, Emiko Mizuta and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yosuke KogueOsaka Research Center for Drug Discovery, Otsuka Pharmaceutical Company, Ltd., Minoh, Osaka, 562-0029, Japan.
Shunya IkedaWorld Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Yuto MaeharaDepartment of Clinical Laboratory and Biomedical Sciences, The University of Osaka Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
Ryuhei KawamotoDepartment of Clinical Laboratory and Biomedical Sciences, The University of Osaka Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.
Makiko SugaDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Shuhei KidaDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Kumi ShibataDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Kazuhito TsutsumiDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Hiraku MurakamiDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Emiko MizutaDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Yo MizutaniDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Yuta YamaguchiDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Daisuke OkuzakiGenome Information Research Center, Research Institute for Microbial Diseases, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Naoki HosenDepartment of Hematology and Oncology, The University of Osaka Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

Funding

Japan Agency for Medical Research and Development 21bm0404076h0001Japan Society for the Promotion of Science JP21K19508, JP23K18300, and JP23H04781
6 · The paper itself

Abstract

Cord blood (CB)-derived chimeric antigen receptor (CAR) natural killer (NK) cells have demonstrated significant antitumor efficacy. We recently reported that CB-derived CAR NK cells predominantly originate from CD7

Indexed as

Fetal BloodImmunotherapy, AdoptiveKiller Cells, NaturalReceptors, Chimeric AntigenReceptors, Interleukin-154-1BB LigandAnimalsFeeder CellsHumansInterleukin-15Interleukin-21InterleukinsK562 CellsMiceMice, Inbred NODMice, SCID4-1BB LigandInterleukin-15Interleukin-21InterleukinsReceptors, Chimeric AntigenReceptors, Interleukin-15Adoptive cell therapyCAR NK cellCord bloodIL-15NK cellProgenitor cell

Identifiers

PMID41081911
PMCPMC12518728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.